Innovator Ibd 50 Etf Beta
| FFTY Etf | USD 29.84 0.67 2.30% |
Innovator IBD 50 fundamentals help investors to digest information that contributes to Innovator IBD's financial success or failures. It also enables traders to predict the movement of Innovator Etf. The fundamental analysis module provides a way to measure Innovator IBD's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovator IBD etf.
Innovator |
Innovator IBD 50 ETF Beta Analysis
Innovator IBD's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Innovator IBD Beta | 1.41 |
Most of Innovator IBD's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovator IBD 50 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Innovator IBD 50 has a Beta of 1.41. This is much higher than that of the Innovator ETFs family and significantly higher than that of the Mid-Cap Growth category. The beta for all United States etfs is notably lower than that of the firm.
Innovator Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovator IBD's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Innovator IBD could also be used in its relative valuation, which is a method of valuing Innovator IBD by comparing valuation metrics of similar companies.Innovator IBD is currently under evaluation in beta as compared to similar ETFs.
Fund Asset Allocation for Innovator IBD
The fund invests 99.92% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Innovator IBD's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Innovator IBD will likely underperform.
Innovator Fundamentals
| Price To Earning | 24.64 X | |||
| Price To Book | 3.76 X | |||
| Price To Sales | 3.74 X | |||
| Number Of Employees | 366 | |||
| Beta | 1.41 | |||
| Total Asset | 97.73 M | |||
| One Year Return | 23.60 % | |||
| Three Year Return | (9.90) % | |||
| Five Year Return | (2.40) % | |||
| Net Asset | 97.73 M | |||
| Last Dividend Paid | 0.0568 | |||
| Equity Positions Weight | 99.92 % |
About Innovator IBD Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovator IBD 50's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovator IBD using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovator IBD 50 based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innovator IBD 50 offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innovator IBD's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innovator Ibd 50 Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Innovator Ibd 50 Etf:Check out Innovator IBD Piotroski F Score and Innovator IBD Altman Z Score analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
The market value of Innovator IBD 50 is measured differently than its book value, which is the value of Innovator that is recorded on the company's balance sheet. Investors also form their own opinion of Innovator IBD's value that differs from its market value or its book value, called intrinsic value, which is Innovator IBD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innovator IBD's market value can be influenced by many factors that don't directly affect Innovator IBD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innovator IBD's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innovator IBD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innovator IBD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.